FURTHER CHARACTERICATION OF AGONIST EFFECTS OF FLUMAZENIL

氟马西尼激动剂作用的进一步表征

• 批准号: 6115978
• 负责人: Warren K Bickel
• 金额: $ 3.29万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115978
• 关键词: benzodiazepine receptor; benzodiazepines; caffeine; drug interactions; human subject; inhibitor /antagonist; midazolam; sensory discrimination

The novel-response drug discrimination procedure is one of several three-choice procedures developed to address interpretational difficulties that can occur under standard two-response procedures. The novel-response procedure is unique among three-choice discrimination procedures by using instructions, rather than explicit training procedures. With the novel-response procedure, participants are trained under a standard two-response (drug versus placebo) discrimination, and then instructed that in the presence of a drug stimulus unlike either of the training drugs, responses should be made on the novel-response alternative. Several studies have assessed the utility of the novel-response procedure by comparing effects under a standard two-response and the novel-response procedure in participants trained to discriminate triazolam from placebo. Results indicate that the novel-response procedure can increase the selectivity of both placebo- and drug-appropriate responding, and in this way, allows for finer distinctions to be made among sedatives than a standard two-response procedure.

新反应药物歧视程序是为解决在标准两反应程序下可能出现的解释困难而开发的几种三选程序之一。新反应程序是三种选择歧视程序中的独特之处，它使用指令，而不是明确的培训程序。通过新反应程序，参与者在标准的双反应(药物与安慰剂)区分下接受培训，然后指示在存在与训练药物中的任何一种不同的药物刺激时，应对新反应替代药物做出反应。一些研究通过比较标准双反应程序和新反应程序在受试者中的效果来评估新反应程序的实用性，这些受试者接受了区分三唑仑和安慰剂的培训。结果表明，新反应程序可以增加安慰剂反应和药物适当反应的选择性，这样，与标准的两反应程序相比，可以在镇静剂之间进行更细微的区分。